Xipamide

Xipamide

Clinical data
AHFS/Drugs.com	International Drug Names
Pregnancy category	contraindication
Routes of administration	oral
ATC code	C03BA10 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	95%
Protein binding	98%
Metabolism	glucuronide (30%)
Elimination half-life	5.8 to 8.2 hours
Excretion	renal (1/3) and biliary (2/3)
Identifiers
IUPAC name 4-chloro-N-(2,6-dimethylphenyl)-2-hydroxy-5-sulfamoylbenzamide
CAS Number	14293-44-8 Y
PubChem CID	26618
ChemSpider	24795 N
UNII	4S9EY0NUEC
KEGG	D06341 Y
ChEMBL	ChEMBL517199 N
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C15H15ClN2O4S
Molar mass	354.80 g/mol
3D model (JSmol)	Interactive image
SMILES CC1=C(C(=CC=C1)C)NC(=O)C2=CC(=C(C=C2O)Cl)S(=O)(=O)N
InChI InChI=1S/C15H15ClN2O4S/c1-8-4-3-5-9(2)14(8)18-15(20)10-6-13(23(17,21)22)11(16)7-12(10)19/h3-7,19H,1-2H3,(H,18,20)(H2,17,21,22) N Key:MTZBBNMLMNBNJL-UHFFFAOYSA-N N
NY (what is this?)  (verify)

WikiDoc Resources for Xipamide
Articles
Most recent articles on Xipamide Most cited articles on Xipamide Review articles on Xipamide Articles on Xipamide in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Xipamide Images of Xipamide Photos of Xipamide Podcasts & MP3s on Xipamide Videos on Xipamide
Evidence Based Medicine
Cochrane Collaboration on Xipamide Bandolier on Xipamide TRIP on Xipamide
Clinical Trials
Ongoing Trials on Xipamide at Clinical Trials.gov Trial results on Xipamide Clinical Trials on Xipamide at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Xipamide NICE Guidance on Xipamide NHS PRODIGY Guidance FDA on Xipamide CDC on Xipamide
Books
Books on Xipamide
News
Xipamide in the news Be alerted to news on Xipamide News trends on Xipamide
Commentary
Blogs on Xipamide
Definitions
Definitions of Xipamide
Patient Resources / Community
Patient resources on Xipamide Discussion groups on Xipamide Patient Handouts on Xipamide Directions to Hospitals Treating Xipamide Risk calculators and risk factors for Xipamide
Healthcare Provider Resources
Symptoms of Xipamide Causes & Risk Factors for Xipamide Diagnostic studies for Xipamide Treatment of Xipamide
Continuing Medical Education (CME)
CME Programs on Xipamide
International
Xipamide en Espanol Xipamide en Francais
Business
Xipamide in the Marketplace Patents on Xipamide
Experimental / Informatics
List of terms related to Xipamide

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Xipamide is a sulfonamide diuretic drug marketed by Eli Lilly under the trade names Aquaphor (in Germany) and Aquaphoril (in Austria). It is used for the treatment of oedema and hypertension.

Mechanism of Action

Like the structurally related thiazide diuretics, xipamide acts on the kidneys to reduce sodium reabsorption in the distal convoluted tubule. This increases the osmolarity in the lumen, causing less water to be reabsorbed by the collecting ducts. This leads to increased urinary output. Unlike the thiazides, xipamide reaches its target from the peritubular side (blood side).

Additionally, it increases the secretion of potassium in the distal tubule and collecting ducts. In high doses it also inhibits the enzyme carbonic anhydrase which leads to increased secretion of bicarbonate and alkalizes the urine.

Unlike with thiazides, only terminal renal failure renders xipamide ineffective.

Uses

Xipamide is used for

• cardiac oedema caused by decompensation of heart failure
• renal oedema, chronic renal disease (but not with anuria)
• hepatic oedema caused by cirrhosis
• ascites
• lymphoedema
• hypertension in combination with chronic renal disease

Pharmacokinetics

After oral administration, 20 mg of xipamide are resorbed quickly and reach the peak plasma concentration of 3 mg/l within an hour. The diuretic effect starts about an hour after administration, reaches its peak between the third and sixth hour, and lasts for nearly 24 hours.

One third of the dose is glucuronidized, the rest is excreted directly through the kidney (1/3) and the faeces (2/3). The total plasma clearance is 30-40 ml/min. Xipamide can be filtrated by haemodialysis but not by peritoneal dialysis.

Dosage

Initially 40 mg, it can be reduced to 10–20 mg to prevent a relapse.

The lowest effective dose is 5 mg. More than 60 mg have no additional effects.

Adverse Effects

• more than 1/10 of all patients
  • hypokalaemia, which can lead to nausea, muscular weakness or cramps, and ECG abnormities
• 1/100 to 1/10
  • hyponatraemia, which can lead to headache, nausea, drowsiness or confusion
  • orthostatic hypotension
  • initially increase of urea, uric acid and creatinine, which can lead to a gout attack in predisposed patients
• 1/1000 to 1/10,000
  • allergic reactions of the skin
  • hyperlipidaemia
• less than 1/10,000
  • haemorrhagic pancreatitis
  • acute interstitial nephritis
  • thrombocytopenia, leucopenia

Contraindications

• anuria
• praecoma and coma hepaticum
• hypovolemia, hyponatremia, hypokalemia
• hypercalcemia
• gout
• sulfonamide hypersensitivity
• pregnancy, lactation period

Interactions

Not recommended combinations

• Xipamide lowers the renal clearance of lithium which can lead to lithium intoxication. (This interaction is classified as medium.)

Combinations requiring special precautions

The product information requests special precautions for these combinations:

• The antihypertensive effect can be increased by ACE inhibitors, barbiturates, phenothiazines, tricyclic antidepressants, alcohol, etc. (Classified as minor.)

• NSAIDs can reduce the antihypertensive and diuretic effects. Xipamide increases the neurotoxicity of high doses of salicylates. (Classified as minor.)

• Toxicity of cardiac glycosides is increased due to hypokalemia and hypomagnesemia.(Classified as minor.)

• Antiarrhythmic agents (classes Ia and III), phenothiazines and other antipsychotics increase the risk of torsade de pointes due to hypokalemia.

Interactions not included in the product information

• Xipamide can reduce the effect of antidiabetics. (Classified as minor.)

Banned use in sport

On 17 July 2012, cyclist Fränk Schleck was removed from the Tour de France by his team RadioShack-Nissan after his A-sample returned traces of xipamide.